Cold Genesys, Inc., a Santa Ana, CA-based clinical-stage biopharmaceutical company focused on the development of novel immunotherapies, closed a $22m Series C financing.
The round was led by ORI Healthcare Fund L.P., with participation from Perseverance Capital Management.
The company intends to use the funds to accelerate the growth of its ongoing clinical programs and the continued advancement of its lead oncolytic immunotherapy CG0070, which has completed a Phase 2 study (BOND2) and demonstrated clinical safety and efficacy in over 100 patients to date for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC).
Led by Arthur Kuan, CEO, Cold Genesys is a clinical-stage immuno-oncology company focused on the development of oncolytic immunotherapies to combat cancer. The company’s lead candidate CG0070 has completed an investigation in a Phase 2, single-arm, open-label, multicenter study (BOND2) for patients with NMIBC who failed BCG therapy and refused cystectomy. In addition, Cold Genesys is exploring the use of CG0070 in combination with immune checkpoint modulators in different solid tumors.